# Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

> **NCT00072566** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Primary Peritoneal Carcinoma
- Recurrent Ovarian Carcinoma
- Stage IV Ovarian Cancer

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cyclophosphamide
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00072566
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072566, "Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00072566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*